Monday, April 6, 2020

Refuge Biotechnologies: Developing “Smart Cells” to Fight Cancer Inside the Human Body

Cell therapy is an emerging treatment with great potential because, unlike small molecules, cells are dynamic. They can migrate, proliferate, differentiate, and respond to their environment both in vitro and in vivo. Cell therapy company Refuge Biotechnologies, based in Menlo Park,...

RAPT Therapeutics Sees “Charged” Lung Cancer Tumors as Inviting Targets for Lead Drug FLX475

Lung cancer remains a stubborn disease to treat. Even cutting-edge immuno-therapies have had limited success. Brian Wong, CEO of South San Francisco-based RAPT Therapeutics, believes that the company’s lead drug, FLX475, has potential to overcome the scientific challenges in treating this disease.

SQZ Biotech’s Unique Technology Squeezes Cells to Transform Them into Therapeutics

SQZ Biotechnologies’ technology platform aims to tap into cells to create the next generation of commercially viable therapeutics with the potential to have an impact treating a broad range of diseases. Unlike current gene and cell therapies, which use...

Avalon Venture’s Jay Lichter Discusses COI, Community of Innovation, a Different Way for Drug Discovery and Development

By Rich Soll, Senior Advisor, Strategic Initiatives, WuXi AppTec (@richsollwx) and WuXi AppTec Content Team Tucked away in the life science corridor of San Diego’s famed Torrey Pines Road is an unconventional incubator with an unconventional name, COI Pharmaceuticals....

The Prostate Cancer Foundation: A Tireless Worker and Voice in the Development for Better Treatments

Prostate cancer is the second most common cancer in men.It is a cancer that occurs in the prostate — a small walnut-shaped gland in men that produces the seminal fluid that nourishes and transports sperm. While some types of prostate cancer grow...

SUBSCRIBE TO OUR NEWSLETTER

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WUXI NEWS

WuXi AppTec Reports Strong 2019 Annual Results

WuXi AppTec Reports Strong 2019 Annual Results Revenue Growth Accelerated 33.9% Year-Over-Year to RMB12,872 Million Adjusted...